JMIR Publications

ABSTRACT

Background:

Bariatric weight loss surgery rates are increasing internationally. The novel Endoscopic Sleeve Gastroplasty (ESG) is a minimally-invasive endoscopic procedure thought to mimic some of the effects of the more common surgical Laparoscopic Sleeve Gastrectomy (LSG).

Objective:

This formative study aimed to determine the pre- and early postoperative characteristics of adults, matched for age, sex, and body mass index (BMI) who elected ESG versus LSG.

Methods:

A prospective cohort study recruited ESG and matched LSG adults in Australia. Preoperative outcomes were medical characteristics, blood pathology, blood pressure, gastrointestinal symptoms, weight-related quality of life, body composition and adverse events recorded preoperatively and up to 2-weeks postoperatively.

Results:

50 (n=25 ESG, n=25 LSG) patients were primarily Caucasian (90%) females (82%), mean age 41.7 (SD: 9.4) years. Participants had mean 4.0 (SD: 2.2) active comorbid conditions. There was a 2.4kg/m2 difference in median body mass index (p=0.024) between groups, but fat and fat free mass had no statistically significant difference. For every percent improvement in weight-related self-esteem, the odds for selecting ESG increased by 4.4% (95%CI:1.004,1.085; p=0.032). For every percent worsening in hunger pain, the odds for selecting ESG decreased by 3.3% (95%CI:0.944,0.990; p=0.004).

Conclusions:

Australian adults who elected an endoscopic versus surgical sleeve had similar rates of comorbidities, body fat percentage, and weight-related quality of life. Lower self-esteem predicted electing a more invasive sleeve (LSG over ESG). Clinical Trial: World Health Organisation Universal Trial Number: U1111-1216-8678; Australia New Zealand Clinical Trials Registry Number: ACTRN12618000337279.